Drugs / 5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00385788 Background | Jul 2005 → Aug 2016 | Hodgkins lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00385788 ↗ |